Zenith Epigenetics
develops and commercializes bromodomain inhibitors for the treatment of cancer and other infectious diseases... Read moreZenith Epigenetics
develops and commercializes bromodomain inhibitors for the treatment of cancer and other infectious diseases... Read more
President & CEO
Donald McCaffrey
News
May 12, 2026
FinanzNachrichten
Zenith Epigenetics: Zenith Capital Corp.: Zenith Capital Corp. Amends Promissory Notes
Apr 09, 2026
FinanzNachrichten
Zenith Epigenetics: Zenith Capital Corp.: Zenith Epigenetics Provides Update on ZEN-3694 NUT Carcinoma Program
Mar 31, 2026
Marketscreener
Zenith Epigenetics: Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026
Dec 23, 2025
Marketscreener
Zenith Epigenetics: Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025
Nov 26, 2025
Marketscreener
Zenith Epigenetics: Zenith Capital Corporation Reports Earnings Results for the Full Year Ended July 31, 2025
Oct 28, 2025
Pharmabiz
Zenith Epigenetics: US FDA grants orphan drug designation to Zenith Epigenetics' ZEN3694 to treat NUT carcinoma
Jun 20, 2025
Marketscreener
Zenith Epigenetics: Zenith Capital Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2025
Dec 24, 2024
Marketscreener
Zenith Epigenetics: Zenith Capital Corporation Reports Earnings Results for the First Quarter Ended October 31, 2024
Dec 18, 2024
Marketscreener
Zenith Epigenetics: Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024
Dec 16, 2024
FinanzNachrichten
Zenith Epigenetics: Zenith Capital Corp. Provides Update on the Company's Upcoming Annual General Meeting
Zenith Epigenetics Competitors
1
2
3
4
5
6
7
8
9
10